Novartis: Coronary Artery Disease trials
The registry lists 10 Coronary Artery Disease studies with Novartis as lead sponsor. 1 are open to participants now and 6 have results posted.
Phase 2 6Phase 3 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRPRecruitingNCT07830719Phase 2
- Study of the Vascular Effects of SerelaxinCompletedNCT01979614Phase 2Results posted
- Cangrelor to Clopidogrel or Prasugrel Transition StudyCompletedNCT01979445Phase 2Results posted
- Cangrelor Prasugrel Transition StudyCompletedNCT01852019Phase 2Results posted
- Cangrelor Ticagrelor Transition StudyCompletedNCT01766466Phase 2Results posted
- Efficacy of LCQ908 on Cardiovascular RiskTerminatedNCT01474434Phase 2Results posted
- Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease PatientsCompletedNCT00853827Phase 3Results posted
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Active, not recruitingNCT05739383Phase 3
- Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular EventsActive, not recruitingNCT05360446Phase 3
- Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head ComparisonCompletedNCT01379677Phase 3